Company intelligence / Profile preview

Bio-Path Holdings, Inc.

Bellaire, Texas, United Statesbiopathholdings.com ↗

Ownership: Public · BPTH
Development stage: Phase 2

Overview

The company has multiple ongoing clinical trials. Their Phase 1/1b trial of BP1002 for AML showed a meaningful patient response with stable disease and significant reduction in blast count after one treatment cycle. Their Phase 2 trial for prexigebersen in AML is ongoing, and they've developed a molecular biomarker package to identify patients more likely to respond to treatment.

Therapeutic areas: OncologyEndocrinologyHematology
Modalities: RNAi nanoparticle drugsantisense oligodeoxynucleotidesDNA therapeutics
Industry: Biotech

Drug pipeline

3 assets

prexigebersen

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $280.3K
Total revenue: $0
Enterprise value: $798.3K

Beyond the preview

Go deeper on Bio-Path Holdings, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-Path Holdings, Inc..

Explore the full profile